Cognigenics

Executive Summary

Cognigenics is a private biotechnology company pioneering a non-invasive intranasal RNA interference (RNAi) platform, iRNAi™, designed to deliver programmable therapeutics directly to the brain. Founded in 2020 and based in San Diego, the company aims to address the critical challenge of crossing the blood-brain barrier to treat neuropsychiatric disorders such as depression, anxiety, and cognitive decline. By precisely modulating neural circuits, Cognigenics' technology offers the potential for durable, targeted treatments with fewer systemic side effects than current modalities. The platform's programmability enables rapid adaptation to multiple indications, positioning it as a versatile tool in neuroscience. As an early-stage entity, Cognigenics is focused on advancing its lead candidate through preclinical development. Key upcoming catalysts include the completion of pivotal animal studies demonstrating proof-of-concept for its iRNAi platform, which could validate brain delivery and target engagement. An Investigational New Drug (IND) application is anticipated within 12-18 months, marking a critical regulatory milestone. Additionally, the company may seek strategic partnerships or licensing deals with larger pharmaceutical firms to accelerate clinical translation. While the technology is promising, Cognigenics faces typical early-stage risks, including technical validation, manufacturing scalability, and funding. Its success hinges on generating robust preclinical data and securing resources for clinical trials.

Upcoming Catalysts (preview)

• Q3 2026Completion of pivotal preclinical proof-of-concept studies70% success
• Q1 2027IND submission for lead candidate50% success
• TBDStrategic partnership or licensing deal30% success